MSH3 Mismatch Repair Protein Regulates Sensitivity to Cytotoxic Drugs and a Histone Deacetylase Inhibitor in Human Colon Carcinoma Cells
Jae Myung Park(The Catholic University of Korea Seoul St. Mary's Hospital), Frank A. Sinicrope(Mayo Clinic in Arizona)
Cited by 44
Related Papers
DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy
|JNCI Journal of the National Cancer Institute|2011|527
A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening
|New England Journal of Medicine|2024|385
Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy
|JAMA Oncology|2017|146
Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer
|Clinical Gastroenterology and Hepatology|2016|115
Sorafenib Inhibits STAT3 Activation to Enhance TRAIL-Mediated Apoptosis in Human Pancreatic Cancer Cells
|Molecular Cancer Therapeutics|2010|93